Mesoblast Limited’s FDA-approved Ryoncil and advancing Revascor target major conditions like SR-aGVHD and heart failure. See ...

Many mitochondrial diseases have been difficult to study and treat due to the inherent challenges in accessing mitochondrial DNA (mtDNA). Now, researchers have optimized mitochondrial-targeted ...

Zevaskyn won FDA approval upon Abeona’s second filing of a biologics license application (BLA) for the therapy.

Researchers at the University of Minnesota have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) ...

Researchers have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) cancers. The results show ...

Gene therapy has emerged as a promising approach to previously untreatable conditions, including Duchenne muscular dystrophy (DMD), a progressive disorder caused by DMD mutations that leads to early ...

Researchers at the University of Minnesota have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing ...

HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and ...

APLA Health proudly celebrates the grand reopening of its Long Beach Health Center, unveiling a significant expansion that ...

RoosterBio Inc. has partnered with Thermo Fisher Scientific to accelerate the availability of new, potentially life-saving ...